Page 314 - Haematologica March 2020

C. Zaninetti et al.
9. Pecci A, Gresele P, Klersy C, et al.
Eltrombopag for the treatment of the inher- ited thrombocytopenia deriving from MYH9 mutations. Blood. 2010;116(26): 5832-5837.
10. Pecci A, Barozzi S, d'Amico S, Balduini CL. Short-term eltrombopag for surgical prepa- ration of a patient with inherited thrombo- cytopenia deriving from MYH9 mutation. Thromb Haemost. 2012;107(6):1188-1189.
11. Favier R, Feriel J, Favier M, Denoyelle F, Martignetti JA. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia. Pediatrics. 2013;132(3):e793-795.
12. Favier R, De Carne C, Elefant E, Lapusneanu R, Gkalea V, Rigouzzo A. Eltrombopag to treat thrombocytopenia during last month of pregnancy in a woman with MYH9-relat- ed disease: a case report. A A Pract. 2018;10(1):10-12.
13. Gröpper S, Althaus K, Najm J, et al. A patient with Fechtner syndrome successfully treated with romiplostim. Thromb Haemost. 2012;107(3):590-591.
14. Fiore M, Saut N, Alessi MC, Viallard JF. Successful use of eltrombopag for surgical preparation in a patient with ANKRD26- related thrombocytopenia. Platelets. 2016;27(8):828-829.
15. Westbury SK, Downes K, Burney C, et al. Phenotype description and response to thrombopoietin receptor agonist in DIAPH1-related disorder. Blood Adv. 2018;2(18):2341-2346.
16. Yamanouchi J, Hato T, Kunishima S, Niiya T, Nakamura H, Yasukawa M. A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia. Ann Hematol. 2015;94(9);1599-1600.
17. Gabelli M, Marzollo A, Notarangelo LD, Basso G, Putti MC. Eltrombopag use in a patient with Wiskott-Aldrich syndrome. Pediatr Blood Cancer. 2017;64(12).
18. Gerrits AJ, Leven EA, Frelinger AL 3rd, et al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syn- drome/X-linked thrombocytopenia. Blood. 2015;126(11):1367-1378.
19. Noris P, Perrotta S, Seri M, et al. Mutations
in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analy- sis of 78 patients from 21 families. Blood. 2011;117(24):6673-6680.
20. Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 2010;115(16):3231-3238.
21. Massaad MJ, Ramesh N, Geha RS. Wiskott- Aldrich syndrome: a comprehensive review. Ann N Y Acad Sci. 2013;1285:26-43.
22. Noris P, Perrotta S, Bottega R, et al. Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombo- cytopenia derived from the monoallelic Ala156Val mutation of GPIb (Bolzano mutation). Haematologica. 2012;97(1):82- 88.
23. Gresele P, Falcinelli E, Giannini S, et al. Dominant inheritance of a novel integrin β3 mutation associated with a hereditary macrothrombocytopenia and platelet dys- function in two Italian families. Haematologica. 2009;94(5):663-669.
24. Michelson AD, Barnard MR, Krueger LA, Frelinger AL 3rd, Furman MI. Evaluation of platelet function by flow cytometry. Methods. 2000;21(3):259-270.
25. Pecci A. Pathogenesis and management of inherited thrombocytopenias; rationale for the use of thrombopoietin-receptor ago- nists. Int J Hematol. 2013;98(1):34-47.
26. Pecci A, Balduini CL. Lessons in platelet pro- duction from inherited thrombocytopenias. Br J Haematol. 2014;165(2):179-192.
27. Balduini CL, Savoia A, Seri M. Inherited thrombocytopenias frequently diagnosed in adults. J Thromb Haemost. 2013;11(6):1006- 1019.
28. Rodeghiero F, Pecci A, Balduini CL. Thrombopoietin receptor agonists in hered- itary thrombocytopenias. J Thromb Haemost. 2018;16(9):1700-1710.
29. Daskalakis M, Colucci G, Keller P, et al. Decreased generation of procoagulant platelets detected by flow cytometric analy- sis in patients with bleeding diathesis. Cytometry B Clin Cytom. 2014;86(6):397- 409.
30. Wong RSM, Saleh MN, Khelif A, et al.
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527-2536.
31. Pecci A, Klersy C, Gresele P, et al. MYH9- related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations. Hum Mutat. 2014;35(2):236-247.
32. Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplas- tic syndrome and thrombocytopenia. Cancer. 2014;120(12):1838-1846.
33. Platzbecker U, Wong RS, Verma A, et al. Safety and tolerability of eltrombopag ver- sus placebo for treatment of thrombocy- topenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, ran- domised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015;2(10):e417-426.
34. Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombo- cytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4(3):e127-e136.
35. Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for advanced myelodys- plastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018;(1):e34- e43.
36. Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132(25):2629-2638.
37. Noris P, Favier R, Alessi MC, et al. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood. 2013;122(11): 1987-1989.
38. Noris P, Pecci A. Hereditary thrombocytope- nias: a growing list of disorders. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):385-399.
828
haematologica | 2020; 105(3)